Recursion Pharmaceuticals (RXRX) Total Debt (2020 - 2026)

Recursion Pharmaceuticals has reported Total Debt for 7 years, with the latest figure at $16.4 million in Q1 2026.

• For the quarter ending Q1 2026, Total Debt fell 34.3% year-over-year to $16.4 million; the trailing twelve-month figure through Mar 2026 stood at $16.4 million (down 34.3% YoY), and the FY2025 full-year result was $18.7 million, down 32.03% from the prior year.
• Total Debt for Q1 2026 stood at $16.4 million, down from $18.7 million in the prior quarter.
• The five-year high for Total Debt was $31.0 million in Q2 2024, with the low at $536000.0 in Q4 2022.
• Historically, Total Debt has averaged $11.7 million across 5 years, with a median of $1.2 million in 2023.
• Annual changes were most pronounced in 2022 — Total Debt plunged 94.1% — and 2024, when it surged 2586.58%.
• Recursion Pharmaceuticals' Total Debt stood at $536000.0 in 2022, then soared by 113.06% to $1.1 million in 2023, then jumped by 2303.42% to $27.4 million in 2024, then tumbled by 32.03% to $18.7 million in 2025, then decreased by 11.84% to $16.4 million in 2026.
• The last three Total Debt figures came in at $16.4 million (Q1 2026), $18.7 million (Q4 2025), and $20.8 million (Q3 2025), per Business Quant data.